For Uninfected Individuals For Educators | REMS Web Site |E-mail this site
CLOSE

Prescribing TRUVADA for PrEP

TRUVADA for PrEP must only be prescribed as part of a comprehensive prevention strategy that includes other prevention measures, such as safer sex practices, because TRUVADA is not always effective in preventing the acquisition of HIV-1. Counsel uninfected individuals about safer sex practices that include:

  • Consistent and correct use of condoms
  • Limiting the number of sexual partners
  • Knowledge of their HIV-1 status and that of their partner(s)
  • Regular testing for other sexually transmitted infections that can facilitate HIV-1 transmission (such as syphilis and gonorrhea)

Uninfected individuals should also be counseled to strictly adhere to the recommended daily dosing schedule. The effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 is strongly correlated with adherence as demonstrated by measurable drug levels in clinical trials. Here are the key steps in prescribing TRUVADA for PrEP. For a complete list of prescribing steps, review the Checklist for Prescribers.

  • 1

    Confirm negative HIV-1 status immediately prior to initiating TRUVADA for PrEP.

  • 2

    Prescribe TRUVADA for PrEP as part of a comprehensive prevention strategy.

  • 3

    Counsel individuals on the importance of strict adherence.

  • 4

    Reconfirm negative HIV-1 status at least every 3 months.

Close the layer

By completing the fields below, you can register for subsidized testing for qualified uninfected individuals.

*All fields are required.

Your Information



Your NPI is used to confirm you are a
licensed healthcare provider. Find your NPI



Your Office Address




I understand that Gilead Sciences is offering subsidized HIV-1 testing for individuals who may not otherwise have access to testing due to lack of insurance coverage and/or financial hardship and who are being evaluated for TRUVADA for PrEP as part of a comprehensive HIV prevention strategy that includes counseling, safer sex strategies including the use of condoms, and testing before the initiation of TRUVADA for PrEP using a diagnostic test capable of detecting acute HIV-1 infection and HIV-1 antibody testing at least every 3 months while using TRUVADA for PrEP as described in the TRUVADA Prescribing Information.

I understand that Gilead Sciences is also offering subsidized HBV testing for these individuals prior to initiating TRUVADA for PrEP. It is recommended that all individuals be tested for the presence of chronic hepatitis B virus (HBV) before initiating TRUVADA. TRUVADA is not approved for the treatment of chronic HBV infection and the safety and efficacy of TRUVADA have not been established in patients infected with HBV. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued TRUVADA. In some patients infected with HBV and treated with emtricitabine, the exacerbations of hepatitis B were associated with liver decompensation and liver failure. Patients who are infected with HBV should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with TRUVADA. If appropriate, initiation of anti-hepatitis B therapy may be warranted. HBV-uninfected individuals should be offered vaccination.

By clicking "I agree" in the box below, I agree to utilize subsidized testing only for the purposes described above and where not otherwise prohibited by law.

Thank you


You have now registered to receive HIV testing at no cost for uninfected individuals at high risk. The free test is only available to U.S. patients, excluding Massachusetts residents and beneficiaries of any state or federally funded programs (including, by way of example, Medicare or Medicaid, Medigap, VA, DOD, or TriCare).

LabCorp will contact you with more information.

If you have not received your account information and testing request/lab form to access free HIV and HBV tests within two (2) business days, or have misplaced your account information, please contact LabCorp at 1-800-598-0497. Please allow staff 1 hour to return any messages.


Close

IMPORTANT SAFETY INFORMATION

BOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS, POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B, and RISK OF DRUG RESISTANCE WITH USE OF TRUVADA FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION

  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir DF, a component of TRUVADA, in combination with other antiretrovirals.
  • TRUVADA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of TRUVADA have not been established in patients infected with HBV. Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HBV and HIV-1 who have discontinued TRUVADA. Therefore, hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are infected with HBV and discontinue TRUVADA. If appropriate, initiation of anti-hepatitis B therapy may be warranted.
  • TRUVADA for PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and periodically (at least every 3 months) during use. Drug-resistant HIV-1 variants have been identified with use of TRUVADA for PrEP following undetected acute HIV-1 infection. Do not initiate TRUVADA for PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed.

INDICATION

TRUVADA is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and in heterosexual serodiscordant couples.

  • Uninfected individuals at high risk for sexually acquired HIV-1 infections include:
    • individuals with HIV-1 infected partner(s)
    • individuals who engage in sexual activity in a high prevalence area or social network and have one or more of the following: inconsistent or no condom use, diagnosis of sexually transmitted infections (STIs), exchange of sex for commodities (money, food, shelter, drugs), use of illicit drugs or alcohol dependence, incarceration, and/or sexual partners of unknown HIV status with any of the above risk factors.
  • Prescribing considerations before initiating TRUVADA for PrEP:
    • TRUVADA for PrEP must only be prescribed as part of a comprehensive prevention strategy because TRUVADA is not always effective in preventing the acquisition of HIV-1 infection.
    • Uninfected individuals must strictly adhere to their dosing schedule because the effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 is strongly correlated with adherence.
    • HIV-1 negative status must be confirmed prior to initiating TRUVADA for PrEP and at least every 3 months thereafter.
      • If clinical symptoms of acute HIV-1 infection are present and recent exposures (<1 month) are suspected, delay initiating TRUVADA for PrEP for at least 1 month until negative HIV-1 status is reconfirmed.
      • Alternatively, negative HIV-1 status can be confirmed with a test approved by the FDA to aid diagnosis of acute or primary HIV-1 infection.

View full Prescribing Information, including BOXED WARNING


The information in this section is intended for healthcare providers in the United States. To continue to this section, click YES. Click NO to return to the previous page.


Close the layer

You Are Now Leaving

By following this link, you are now leaving start.TRUVADA.com.
These sites are not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for their content or your use of them.

Close the layer

A different indication for Truvada

Truvada is also indicated for the treatment of HIV-1 in combination with other medications.

Close the layer

Sign up for HIV-1
testing reminders

By signing up, individuals will receive an e-mail reminder once a month. Reminders can be canceled at any time.

xGilead respects the privacy of your personal health information. Gilead, and companies providing services to Gilead, may use the information that you provide to send you marketing or informational materials, analyze and use your information to improve or develop services and programs, and contact you about marketing programs or research and health topics that may be of interest to you. Gilead, and companies providing services to Gilead, will not sell or rent your personally identifiable information. For more information regarding our Privacy Policy, click here.

Close the layer

E-mail this page

Submit